AbbVie (ABBV) has been at the centre of significant market activity, with analysts seemingly split on their perspective of the company's trajectory. While Goldman Sachs downgraded the company's stock rating and lowered the price target, Wells Fargo insists that it remains a buy. Despite positive earnings, AbbVie faced volatility, and its stock even saw a dip despite overall market gains. The biopharma titan is seeing investor interest due to its strong oncology portfolio, amid a 6% share price dip.
RINVOQ® - its solution for Giant Cell Arteritis, received
EU approval and has been highly anticipated by the market. AbbVie's successful Q4 confirmed impressive sales and revenues, surpassing many estimates. AbbVie initiatives, such as the acquisition of
Nimble Therapeutics, is seen as a move towards bolstering their immunology pipeline. Despite these advances, AbbVie lowered its 2025 profit forecast due to increased expenses from acquisition costs. Looking forward, AbbVie is also expanding SKYRIZI availability in Canada for ulcerative colitis treatment.
Abbvie ABBV News Analytics from Mon, 11 Nov 2024 08:00:00 GMT to Sat, 12 Apr 2025 10:01:50 GMT -
Rating 5
- Innovation 3
- Information 8
- Rumor -4
